1 November 2018 - In hopes of fending off biosimilar competition for its franchise drug, AbbVie has apparently won the bidding to supply its Humira rheumatoid arthritis treatment to an unspecified European market at a steep 80% discount, according to a Wall Street analyst.

Biosimilars are nearly identical variants of pricey, brand-name biologic drugs, but are expected to cost less while providing the same result in patients. However, the savings are generally expected to be in the range of 20% to 30% off the price of a brand-name biologic, which is why the AbbVie discount in Europe generated some notice this week.

Read Stat News article (subscription required)